The protective role of immunoglobulins in fungal infections and inflammation

Seminars in Immunopathology

Volumn 37, Issue 2, 2015, Pages 187-197

  Elluru, Sri Ramulu ^a   Kaveri, Srini V ^b,c,d,e   Bayry, Jagadeesh ^b,c,d,e  

^a LINKÖPING UNIVERSITY   (Sweden)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY   (India)

Author keywords

Aspergillus; Candida; Fungi; Immunoglobulin; Inflammation; Intravenous immunoglobulin; Therapy Natural antibodies

Indexed keywords

IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; POLYSACCHARIDE; YEAST KILLER FACTOR; FUNGUS ANTIBODY;

ANTIFUNGAL RESISTANCE; BIOFILM; COMPLEMENT ACTIVATION; DRUG CYTOTOXICITY; DRUG HALF LIFE; FUNGUS GROWTH; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; INFLAMMATION; LIPID METABOLISM; MYCOSIS; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; PROTECTION; REVIEW; SERODIAGNOSIS; ANIMAL; DISEASE MODEL; FUNGUS; IMMUNOLOGY; MICROBIOLOGY; MYCOSES;

ANIMALS; ANTIBODIES, FUNGAL; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; FUNGI; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; MYCOSES;

EID: 84925464871     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-014-0466-0     Document Type: Review

References (151)

1. Romani L (2004) Immunity to fungal infections. Nat Rev Immunol 4:1–23
2. Romani L (2011) Immunity to fungal infections. Nat Rev Immunol 11:275–288
3. Wuthrich M, Deepe GS Jr, Klein B (2012) Adaptive immunity to fungi. Annu Rev Immunol 30:115–148
4. Hube B (2009) Fungal adaptation to the host environment. Curr Opin Microbiol 12:347–349
5. Cooney NM, Klein BS (2008) Fungal adaptation to the mammalian host: it is a new world, after all. Curr Opin Microbiol 11:511–516
6. Aimanianda V, Bayry J, Bozza S et al (2009) Surface hydrophobin prevents immune recognition of airborne fungal spores. Nature 460:1117–1121
7. Bayry J, Aimanianda V, Guijarro JI et al (2012) Hydrophobins—unique fungal proteins. PLoS Pathog 8:e1002700
8. Jouault T, Sarazin A, Martinez-Esparza M et al (2009) Host responses to a versatile commensal: PAMPs and PRRs interplay leading to tolerance or infection by Candida albicans. Cell Microbiol 11:1007–1015
9. van de Veerdonk FL, Kullberg BJ, van der Meer JW et al (2008) Host-microbe interactions: innate pattern recognition of fungal pathogens. Curr Opin Microbiol 11:305–312
10. Bourgeois C, Majer O, Frohner IE et al (2010) Fungal attacks on mammalian hosts: pathogen elimination requires sensing and tasting. Curr Opin Microbiol 13:401–408
11. Bromuro C, Torosantucci A, Chiani P et al (2002) Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine. Infect Immun 70:5462–5470
12. Nussbaum G, Yuan R, Casadevall A, Scharff MD (1996) Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans. J Exp Med 183:1905–1909
13. Kuruganti U, Henderson LA, Garner RE et al (1988) Nonspecific and Candida-specific immune responses in mice suppressed by chronic administration of anti-mu. J Leukoc Biol 44:422–433
14. Han Y, Morrison RP, Cutler JE (1998) A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun 66:5771–5776
15. Mukherjee J, Scharff MD, Casadevall A (1992) Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun 60:4534–4541
16. Montagnoli C, Bozza S, Bacci A et al (2003) A role for antibodies in the generation of memory antifungal immunity. Eur J Immunol 33:1193–1204
17. Berland R, Wortis HH (2002) Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 20:253–300
18. Coutinho A, Kazatchkine MD, Avrameas S (1995) Natural autoantibodies. Curr Opin Immunol 7:812–818
19. Hardy RR (2006) B-1 B cells: development, selection, natural autoantibody and leukemia. Curr Opin Immunol 18:547–555
20. Kohler H, Bayry J, Nicoletti A et al (2003) Natural autoantibodies as tools to predict the outcome of immune response? Scand J Immunol 58:285–289
21. Zhou ZH, Wild T, Xiong Y et al (2013) Polyreactive antibodies plus complement enhance the phagocytosis of cells made apoptotic by UV-light or HIV. Sci Rep 3:2271
22. Notkins AL (2004) Polyreactivity of antibody molecules. Trends Immunol 25:174–179
23. Ehrenstein MR, Notley CA (2010) The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol 10:778–786
24. Li W, Fu M, An JG et al (2007) Host defence against C. albicans infections in IgH transgenic mice with V(H) derived from a natural anti-keratin antibody. Cell Microbiol 9:306–315
25. Kaveri SV, Silverman GJ, Bayry J (2012) Natural IgM in immune equilibrium and harnessing their therapeutic potential. J Immunol 188:939–945
26. Tian R, Fu M, Zhang Z et al (2013) In situ IgM production and clonal expansion of B-1 cells in peritoneal cavity promote elimination of C. albicans infection in IgH transgenic mice with VH derived from a natural antibody. PLoS One 8:e60779
27. Cassone A, Conti S, De Bernardis F et al (1997) Antibodies, killer toxins and antifungal immunoprotection: a lesson from nature? Immunol Today 18:164–169
28. Matthews R, Burnie J (2001) Antifungal antibodies: a new approach to the treatment of systemic candidiasis. Curr Opin Investig Drugs 2:472–476
29. Wozniak KL, Wormley FL Jr, Fidel PL Jr (2002) Candida-specific antibodies during experimental vaginal candidiasis in mice. Infect Immun 70:5790–5799
30. Subramaniam KS, Datta K, Quintero E et al (2010) The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans. J Immunol 184:5755–5767
31. Rapaka RR, Ricks DM, Alcorn JF et al (2010) Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumocystis murina. J Exp Med 207:2907–2919
32. Szymczak WA, Davis MJ, Lundy SK et al. (2013) X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection. mBio 4: e00265-13
33. Maiti PK, Kumar A, Kumar R et al (1985) Role of antibodies and effect of BCG vaccination in experimental candidiasis in mice. Mycopathologia 91:79–85
34. Cantorna MT, Balish E (1991) Acquired immunity to systemic candidiasis in immunodeficient mice. J Infect Dis 164:936–943
35. Narayanan R, Joyce WA, Greenfield RA (1991) Gastrointestinal candidiasis in a murine model of severe combined immunodeficiency syndrome. Infect Immun 59:2116–2119
36. Carrow EW, Hector RF, Domer JE (1984) Immunodeficient CBA/N mice respond effectively to Candida albicans. Clin Immunol Immunopathol 33:371–380
37. Wagner RD, Vazquez-Torres A, Jones-Carson J et al (1996) B cell knockout mice are resistant to mucosal and systemic candidiasis of endogenous origin but susceptible to experimental systemic candidiasis. J Infect Dis 174:589–597
38. Casadevall A, Pirofski LA (2012) Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell Host Microbe 11:447–456
39. Moulin V, Andris F, Thielemans K et al (2000) B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med 192:475–482
40. Bayry J, Lacroix-Desmazes S, Donkova-Petrini V et al (2004) Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci U S A 101:14210–14215
41. Bayry J, Lacroix-Desmazes S, Kazatchkine MD et al (2005) Modulation of dendritic cell maturation and function by B lymphocytes. J Immunol 175:15–20
42. Morva A, Lemoine S, Achour A et al (2012) Maturation and function of human dendritic cells are regulated by B lymphocytes. Blood 119:106–114
43. Maddur MS, Kaveri SV, Bayry J (2012) Regulation of human dendritic cells by B cells depends on the signals they receive. Blood 119:3863–3864
44. Berggren O, Hagberg N, Weber G et al (2012) B lymphocytes enhance interferon-alpha production by plasmacytoid dendritic cells. Arthritis Rheum 64:3409–3419
45. Maddur MS, Kaveri SV, Bayry J (2013) Dual role of CpG-stimulated B cells in the regulation of dendritic cells. Arthritis Rheum 65:2215–2216
46. Maddur MS, Sharma M, Hegde P, Stephen-Victor E, Pulendran B, Kaveri SV et al (2014) Human B cells induce dendritic cell maturation and favor Th2 polarization by inducing OX-40 ligand. Nat Commun 5:4092
47. Tristao FS, Panagio LA, Rocha FA et al (2013) B cell-deficient mice display enhanced susceptibility to Paracoccidioides brasiliensis infection. Mycopathologia 176:1–10
48. Xin H, Dziadek S, Bundle DR et al (2008) Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. Proc Natl Acad Sci U S A 105:13526–13531
49. Xin H, Cutler JE (2011) Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis. Clin Vaccine Immunol 18:1656–1667
50. Xin H, Cartmell J, Bailey JJ et al (2012) Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis. PLoS One 7:e35106
51. Torosantucci A, Bromuro C, Chiani P et al (2005) A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 202:597–606
52. Torosantucci A, Chiani P, Bromuro C et al (2009) Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS One 4:e5392
53. Sandini S, La Valle R, Deaglio S et al (2011) A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine. FEMS Immunol Med Microbiol 62:215–224
54. De Bernardis F, Amacker M, Arancia S et al (2012) A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models. Vaccine 30:4490–4498
55. Theus SA, Smulian AG, Steele P et al (1998) Immunization with the major surface glycoprotein of Pneumocystis carinii elicits a protective response. Vaccine 16:1149–1157
56. Zheng M, Ramsay AJ, Robichaux MB et al (2005) CD4+ T cell-independent DNA vaccination against opportunistic infections. J Clin Invest 115:3536–3544
57. Zheng M, Shellito JE, Marrero L et al (2001) CD4+ T cell-independent vaccination against Pneumocystis carinii in mice. J Clin Invest 108:1469–1474
58. Rosas AL, Nosanchuk JD, Casadevall A (2001) Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection. Infect Immun 69:3410–3412
59. Dromer F, Charreire J, Contrepois A et al (1987) Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun 55:749–752
60. Rodrigues ML, Shi L, Barreto-Bergter E et al (2007) Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection. Clin Vaccine Immunol 14:1372–1376
61. Rachini A, Pietrella D, Lupo P et al (2007) An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect Immun 75:5085–5094
62. Yuan R, Casadevall A, Spira G et al (1995) Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J Immunol 154:1810–1816
63. Yuan RR, Spira G, Oh J et al (1998) Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in mice. Infect Immun 66:1057–1062
64. Beenhouwer DO, Shapiro S, Feldmesser M et al (2001) Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans. Infect Immun 69:6445–6455
65. Rivera J, Mukherjee J, Weiss LM et al (2002) Antibody efficacy in murine pulmonary Cryptococcus neoformans infection: a role for nitric oxide. J Immunol 168:3419–3427
66. McClelland EE, Nicola AM, Prados-Rosales R et al (2010) Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J Clin Invest 120:1355–1361
67. Shapiro S, Beenhouwer DO, Feldmesser M et al (2002) Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect Immun 70:2598–2604
68. Rivera J, Casadevall A (2005) Mouse genetic background is a major determinant of isotype-related differences for antibody-mediated protective efficacy against Cryptococcus neoformans. J Immunol 174:8017–8026
69. Nussbaum G, Cleare W, Casadevall A et al (1997) Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exp Med 185:685–694
70. Han Y, Cutler JE (1995) Antibody response that protects against disseminated candidiasis. Infect Immun 63:2714–2719
71. Han Y, Cutler JE (1997) Assessment of a mouse model of neutropenia and the effect of an anti-candidiasis monoclonal antibody in these animals. J Infect Dis 175:1169–1175
72. Han Y, Riesselman MH, Cutler JE (2000) Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect Immun 68:1649–1654
73. Johnson MA, Cartmell J, Weisser NE et al (2012) Molecular recognition of Candida albicans (1–2)-beta-mannan oligosaccharides by a protective monoclonal antibody reveals the immunodominance of internal saccharide residues. J Biol Chem 287:18078–18090
74. Han Y (2010) Efficacy of combination immunotherapy of IgM MAb B6.1 and amphotericin B against disseminated candidiasis. Int Immunopharmacol 10:1526–1531
75. Han Y, Kozel TR, Zhang MX et al (2001) Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J Immunol 167:1550–1557
76. Caesar-TonThat TC, Cutler JE (1997) A monoclonal antibody to Candida albicans enhances mouse neutrophil candidacidal activity. Infect Immun 65:5354–5357
77. Moragues MD, Omaetxebarria MJ, Elguezabal N et al (2003) A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities. Infect Immun 71:5273–5279
78. Brena S, Cabezas-Olcoz J, Moragues MD et al (2011) Fungicidal monoclonal antibody C7 interferes with iron acquisition in Candida albicans. Antimicrob Agents Chemother 55:3156–3163
79. Chaturvedi AK, Kavishwar A, Shiva Keshava GB et al (2005) Monoclonal immunoglobulin G1 directed against Aspergillus fumigatus cell wall glycoprotein protects against experimental murine aspergillosis. Clin Diag Lab Immunol 12:1063–1068
80. Chaturvedi AK, Kumar R, Kumar A et al (2009) A monoclonal IgM directed against immunodominant catalase B of cell wall of Aspergillus fumigatus exerts anti-A. fumigatus activities. Mycoses 52:524–533
81. Appel E, Vallon-Eberhard A, Rabinkov A et al (2010) Therapy of murine pulmonary aspergillosis with antibody-alliinase conjugates and alliin. Antimicrob Agents Chemother 54:898–906
82. Buissa-Filho R, Puccia R, Marques AF et al (2008) The monoclonal antibody against the major diagnostic antigen of Paracoccidioides brasiliensis mediates immune protection in infected BALB/c mice challenged intratracheally with the fungus. Infect Immun 76:3321–3328
83. Gigliotti F, Haidaris CG, Wright TW et al (2002) Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia. Infect Immun 70:1069–1074
84. Wells J, Haidaris CG, Wright TW et al (2006) Complement and Fc function are required for optimal antibody prophylaxis against Pneumocystis carinii pneumonia. Infect Immun 74:390–393
85. Nosanchuk JD, Steenbergen JN, Shi L et al (2003) Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. J Clin Invest 112:1164–1175
86. Shi L, Albuquerque PC, Lazar-Molnar E et al (2008) A monoclonal antibody to Histoplasma capsulatum alters the intracellular fate of the fungus in murine macrophages. Eukaryot Cell 7:1109–1117
87. Guimaraes AJ, Frases S, Gomez FJ et al (2009) Monoclonal antibodies to heat shock protein 60 alter the pathogenesis of Histoplasma capsulatum. Infect Immun 77:1357–1367
88. Zhang MX, Lupan DM, Kozel TR (1997) Mannan-specific immunoglobulin G antibodies in normal human serum mediate classical pathway initiation of C3 binding to Candida albicans. Infect Immun 65:3822–3827
89. Kozel TR, MacGill RS, Percival A et al (2004) Biological activities of naturally occurring antibodies reactive with Candida albicans mannan. Infect Immun 72:209–218
90. Zhang MX, Bohlman MC, Itatani C et al (2006) Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice. Infect Immun 74:362–369
91. Boxx GM, Nishiya CT, Kozel TR et al (2009) Characteristics of Fc-independent human antimannan antibody-mediated alternative pathway initiation of C3 deposition to Candida albicans. Mol Immunol 46:473–480
92. Calcedo R, Ramirez-Garcia A, Abad A et al (2012) Phosphoglycerate kinase and fructose bisphosphate aldolase of Candida albicans as new antigens recognized by human salivary IgA. Rev Iberoam Micol 29:172–174
93. van der Velden WJ, Blijlevens NM, Klont RR et al (2006) Primary hepatic invasive aspergillosis with progression after rituximab therapy for a post transplantation lymphoproliferative disorder. Ann Hematol 85:621–623
94. Gil L, Kozlowska-Skrzypczak M, Mol A et al (2009) Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. Bone Marrow Transplant 43:121–126
95. Goldman DL, Khine H, Abadi J et al (2001) Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 107:E66
96. Pitarch A, Nombela C, Gil C (2011) Prediction of the clinical outcome in invasive candidiasis patients based on molecular fingerprints of five anti-Candida antibodies in serum. Mol Cell Proteomics 10(M110):004010
97. Viudes A, Lazzell A, Perea S et al (2004) The C-terminal antibody binding domain of Candida albicans mp58 represents a protective epitope during candidiasis. FEMS Microbiol Lett 232:133–138
98. Rodrigues ML, Travassos LR, Miranda KR et al (2000) Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth. Infect Immun 68:7049–7060
99. Fleuridor R, Zhong Z, Pirofski L (1998) A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis. J Infect Dis 178:1213–1216
100. Larsen RA, Pappas PG, Perfect J et al (2005) Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother 49:952–958
101. Casadevall A, Cleare W, Feldmesser M et al (1998) Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother 42:1437–1446
102. Matthews RC, Burnie JP, Tabaqchali S (1984) Immunoblot analysis of the serological response in systemic candidosis. Lancet 2:1415–1418
103. Matthews RC, Burnie JP, Tabaqchali S (1987) Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterization of serological response to Candida albicans. J Clin Microbiol 25:230–237
104. Swoboda RK, Bertram G, Budge S et al (1995) Structure and regulation of the HSP90 gene from the pathogenic fungus Candida albicans. Infect Immun 63:4506–4514
105. Matthews RC, Burnie JP (2004) Recombinant antibodies: a natural partner in combinatorial antifungal therapy. Vaccine 22:865–871
106. Pachl J, Svoboda P, Jacobs F et al (2006) A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 42:1404–1413
107. Hodgetts S, Nooney L, Al-Akeel R et al (2008) Efungumab and caspofungin: pre-clinical data supporting synergy. J Antimicrob Chemother 61:1132–1139
108. Richie DL, Ghannoum MA, Isham N et al (2012) Nonspecific effect of Mycograb on amphotericin B MIC. Antimicrob Agents Chemother 56:3963–3964
109. Krause I, Wu R, Sherer Y et al (2002) In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations—a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med 12:133–139
110. Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747–755
111. Kaveri SV, Maddur MS, Hegde P et al (2011) Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol 164:2–5
112. Negi VS, Elluru S, Siberil S et al (2007) Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 27:233–245
113. Bayry J, Negi VS, Kaveri SV (2011) Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol 7:349–359
114. Dalakas MC (2004) Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291:2367–2375
115. Nussinovitch U, Shoenfeld Y (2008) Intravenous immunoglobulin—indications and mechanisms in cardiovascular diseases. Autoimmun Rev 7:445–452
116. Mazer BD, Gelfand EW (1991) An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma. J Allergy Clin Immunol 87:976–983
117. Spahn JD, Leung DY, Chan MT et al (1999) Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. J Allergy Clin Immunol 103:421–426
118. Kishiyama JL, Valacer D, Cunningham-Rundles C et al (1999) A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma. Clin Immunol 91:126–133
119. Salmun LM, Barlan I, Wolf HM et al (1999) Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: a double-blind, placebo-controlled, randomized trial. J Allergy Clin Immunol 103:810–815
120. Toledo F, Silvestre JF, Munoz C (2012) Combined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis. Report of four cases. J Eur Acad Dermatol Venereol 26:1325–1327
121. Turner PJ, Kakakios A, Wong LC et al (2012) Intravenous immunoglobulin to treat severe atopic dermatitis in children: a case series. Pediatr Dermatol 29:177–181
122. Kaufman GN, Massoud AH, Audusseau S et al (2011) Intravenous immunoglobulin attenuates airway hyperresponsiveness in a murine model of allergic asthma. Clin Exp Allergy 41:718–728
123. Massoud AH, Guay J, Shalaby KH et al (2012) Intravenous immunoglobulin attenuates airway inflammation through induction of forkhead box protein 3-positive regulatory T cells. J Allergy Clin Immunol 129:1656-1665
124. Araujo LM, Chauvineau A, Zhu R et al (2011) Cutting edge: intravenous Ig inhibits invariant NKT cell-mediated allergic airway inflammation through FcgammaRIIIA-dependent mechanisms. J Immunol 186:3289–3293
125. Batard T, Zimmer A, Nony E et al (2012) Anti-inflammatory activity of sublingual immunoglobulin (SLIG) in a murine model of allergen-driven airway inflammation. Vaccine 30:5666–5674
126. Massoud AH, Yona M, Xue D et al (2014) Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells. J Allergy Clin Immunol 133:853-863
127. Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670–673
128. Tha-In T, Bayry J, Metselaar HJ et al (2008) Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 29:608–615
129. Bayry J, Lacroix-Desmazes S, Carbonneil C et al (2003) Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101:758–765
130. Seite JF, Shoenfeld Y, Youinou P et al (2008) What is the contents of the magic draft IVIg? Autoimmun Rev 7:435–439
131. Ballow M (2011) The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 127:315–323
132. Maddur MS, Kaveri SV, Bayry J (2011) Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmun Rev 10:809–810
133. Maddur MS, Hegde P, Sharma M et al (2011) B cells are resistant to immunomodulation by ‘IVIg-educated’ dendritic cells. Autoimmun Rev 11:154–156
134. Aubin E, Lemieux R, Bazin R (2010) Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood 115:1727–1734
135. Maddur MS, Vani J, Hegde P et al (2011) Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J Allergy Clin Immunol 127:823-830
136. Othy S, Hegde P, Topcu S et al (2013) Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis. J Immunol 190:4535–4541
137. Ramakrishna C, Newo AN, Shen YW et al (2011) Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis. PLoS Pathog 7:e1002071
138. Trinath J, Hegde P, Sharma M et al (2013) Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood 122:1419–1427
139. Schwab I, Nimmerjahn F (2013) Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 13:176–189
140. Seite JF, Goutsmedt C, Youinou P et al (2014) Intravenous immunoglobulin induces a functional silencing program similar to anergy in human B cells. J Allergy Clin Immunol 133(181–188):e181–e189
141. Casulli S, Topcu S, Fattoum L et al (2011) A differential concentration-dependent effect of IVIg on neutrophil functions: relevance for anti-microbial and anti-inflammatory mechanisms. PLoS One 6:e26469
142. Semple JW, Kim M, Hou J et al (2012) Intravenous immunoglobulin prevents murine antibody-mediated acute lung injury at the level of neutrophil reactive oxygen species (ROS) production. PLoS One 7:e31357
143. von Gunten S, Vogel M, Schaub A et al (2007) Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol 119:1005–1011
144. Vrugt B, Wilson S, van Velzen E et al (1997) Effects of high dose intravenous immunoglobulin in two severe corticosteroid insensitive asthmatic patients. Thorax 52:662–664
145. Jakobsson T, Croner S, Kjellman NI et al (1994) Slight steroid-sparing effect of intravenous immunoglobulin in children and adolescents with moderately severe bronchial asthma. Allergy 49:413–420
146. Landwehr LP, Jeppson JD, Katlan MG et al (1998) Benefits of high-dose i.v. immunoglobulin in patients with severe steroid-dependent asthma. Chest 114:1349–1356
147. Pashov A, Delignat S, Bayry J et al (2011) Enhancement of the affinity of glucocorticoid receptors as a mechanism underlying the steroid-sparing effect of intravenous immunoglobulin. J Rheumatol 38:2275
148. Magliani W, Conti S, de Bernardis et al (1997) Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nat Biotechnol 15:155–158
149. Polonelli L, Magliani W, Conti S et al (2003) Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect Immun 71:6205–6212
150. Cenci E, Mencacci A, Spreca A et al (2002) Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation. Infect Immun 70:2375–2382
151. Polonelli L, De Bernadis F, Conti S et al (1996) Human natural yeast killer toxin-like candidacidal antibodies. J Immunol 156:1880–1885